for males ages 19 years and up (full criteria)
at San Francisco, California
study started
estimated completion
Principal Investigator
Thomas Hope
Photo of Thomas Hope
Thomas Hope



The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.


Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol. PET imaging will begin 50-100 minutes after injection, but may be possible in certain circumstances for imaging to be delayed due to patient workflow or equipment issues

Primary Objective:

Sensitivity on a per-patient and per-region-basis (Table 1) of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.


Prostate Cancer Prostatic Neoplasms Edetic Acid Ga-68 labeled PSMA-11 Positron emission tomography-computed tomography (PET/CT) Positron emission tomography-magnetic resonance imaging (PET/MRI) Ga-68 labeled PSMA-11 PET PSMA


You can join if…

Open to males ages 19 years and up

  1. Male, age ≥ 18.
  2. Histopathologically proven prostate adenocarcinoma.
  3. Concern for metastatic disease in one of the following settings:
  4. Initial staging with intermediate to high risk prostate cancer.
  5. Biochemical recurrence after initial therapy.
  6. Ability to understand a written informed consent document, and the willingness to sign it.

You CAN'T join if...

  1. Patient unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.


  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Thomas Hope
    Thomas Hope, MD, is the Director of Molecular Therapy for the Molecular Imaging and Therapeutics Clinical Section in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He also serves as co-chair of the the Cancer Center’s new Molecular Imaging & Radionuclide Therapy Site Committee.


accepting new patients
Start Date
Completion Date
Thomas Hope
Phase 3
Study Type
Last Updated